← Back to Search

NK Cell Therapy

aNK (NK-92) + N-803 for Merkel Cell Carcinoma

Phase 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of immune cells and a boosting drug in patients with advanced Merkel Cell Carcinoma. The treatment aims to enhance the body's immune response to fight the cancer more effectively. Recent advancements have changed the treatment landscape for patients with advanced Merkel Cell Carcinoma.

Eligible Conditions
  • Merkel Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Overall Response Rate
Overall survival
Quality of life assessment
+2 more
Other study objectives
Exploratory Genomic, Transcriptomic, and Proteomic Analysis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: aNK (NK-92) + N-803Experimental Treatment1 Intervention
aNK (activated NK-92, formerly Neukoplast) and N-803
Group II: aNK (NK-92)Experimental Treatment1 Intervention
aNK (activated NK-92, formerly Neukoplast)

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
66 Previous Clinical Trials
4,752 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top